Article Text

PDF
Results of bevacizumab as the primary treatment for retinal vein occlusions
  1. M S Figueroa1,2,
  2. I Contreras1,
  3. S Noval2,3,
  4. C Arruabarrena2,4
  1. 1Department of Ophthalmology, Hospital Universitario Ramón y Cajal, Madrid, Spain
  2. 2Retina and Vitreous Section, Vissum Corporación Oftalmológica, Madrid, Spain
  3. 3Department of Ophthalmology, Hospital Universitario La Paz, Madrid, Spain
  4. 4Department of Ophthalmology, Hospital Príncipe de Asturias, Alcalá de Henares, Spain
  1. Correspondence to Inés Contreras, Hospital Universitario Ramón y Cajal, c/ Ferraz, n°35, 2° Izquierda, 28008 Madrid, Spain; inescon3{at}yahoo.com

Abstract

Background The purpose of this study is to evaluate the efficacy of intravitreal bevacizumab as the primary treatment of macular oedema due to retinal vein occlusions.

Methods Patients diagnosed as having central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with visual acuity of less than 20/40 and macular oedema with more than 300 μm central retinal thickness were recruited. Patients that had received any prior treatment were excluded. After an initial intravitreal injection of bevacizumab, re-treatment was performed if intraretinal or subretinal fluid with distortion of the foveal depression was found in optical coherence tomography.

Results 18 eyes with CRVO and 28 eyes with BRVO were included. During a 6-month period, the mean number of injections per patient was 3.7 (BRVO group) and 4.6 (CRVO group). In the BRVO group, mean baseline logMAR visual acuity was 0.80 (SD 0.38) and macular thickness was 486.9 μm (SD 138.5 μm). After 6 months, mean logMAR visual acuity improved significantly to 0.44 (SD 0.34), p<0.001. Mean macular thickness decreased significantly to 268.2 μm (SD 62.5 μm), p<0.001. In the CRVO group, mean baseline logMAR visual acuity was 1.13 (SD 0.21) and macular thickness was 536.4 μm (SD 107.1 μm). Mean final logMAR visual acuity improved significantly to 0.83 (SD 0.45), p<0.001. Mean macular thickness decreased significantly to 326.17 μm (SD 96.70 μm), p<0.001.

Conclusions Intravitreal bevacizumab seems to be an effective primary treatment option for macular oedema due to retinal occlusions. Its main drawback is that multiple injections are necessary to maintain visual and anatomic improvements.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Comité de Ética del Hospital Universitario Ramón y Cajal.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.